vTv Therapeutics (NASDAQ: VTVT) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare vTv Therapeutics to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings.

Valuation & Earnings

This table compares vTv Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
vTv Therapeutics $119,000.00 -$52.99 million -4.18
vTv Therapeutics Competitors $260.16 million $66.28 million -6.61

vTv Therapeutics’ peers have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

vTv Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ peers have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for vTv Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics 0 0 4 0 3.00
vTv Therapeutics Competitors 761 3032 11177 227 2.72

vTv Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 135.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.50%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe vTv Therapeutics is more favorable than its peers.

Institutional & Insider Ownership

11.1% of vTv Therapeutics shares are held by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 0.8% of vTv Therapeutics shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares vTv Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
vTv Therapeutics -13,635.29% N/A -33.58%
vTv Therapeutics Competitors -5,511.45% -449.45% -42.34%


vTv Therapeutics peers beat vTv Therapeutics on 7 of the 12 factors compared.

vTv Therapeutics Company Profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.